This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Sepsis	Receptor-interacting serine-threonine kinase 1 (RIPK1); RIPK3 (RIP3)	<p>Mouse studies suggest that inhibition of RIPK1 and/or RIPK3 could help prevent systemic inflammatory response syndrome (SIRS). In mice, Ripk3 deficiency or pretreatment with the RIPK1-specific kinase inhibitor necrostatin-1 decreased hypothermia and mortality from tumor necrosis factor (TNF)-induced SIRS compared with what was seen in wild-type controls or using vehicle, respectively. Next steps could include evaluating the RIPK1 inhibitor in a therapeutic as opposed to prophylactic setting.</p> <p>SciBX 5(3); doi:10.1038/scibx.2012.77 Published online Jan. 19, 2012</p>	Patent and licensing status unavailable	<p>Duprez, L. <i>et al. Immunity</i>; published online Dec. 23, 2011; doi:10.1016/j.immuni.2011.09.020</p> <p>Contact: Peter Vandenabeele, Flanders Institute for Biotechnology (VIB), Ghent, Belgium e-mail: peter.vandenabeele@dmbr.ugent.be</p>